NCT01596816 2026-03-13
CKNO-PRO
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
618 trialsNCT00160979 2026-03-06
Transrectal Tumour Oxygen - US Army
University Health Network, Toronto
Phase 2 Completed
NCT05008900 2026-03-05
TOPP
University Health Network, Toronto
Phase 2 Completed
NCT04443062 2026-02-27
Bullseye
Radboud University Medical Center
Phase 2 Completed
NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT03568188 2026-02-24
FOCALE
Hospices Civils de Lyon
Phase 2 Completed
NCT04461509 2026-02-20
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT00809991 2026-02-18
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03421782 2026-02-17
Fatigue Interventions in Cancer (Exercise Intervention)
University of Utah
Phase 2 Completed
NCT02274779 2026-02-13
OLIGOPELVIS
Institut Cancerologie de l'Ouest
Phase 2 Completed
NCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT02772588 2026-01-27
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03565835 2026-01-26
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
Phase 2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02854436 2025-12-22
Galahad
Janssen Research & Development, LLC
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT04631744 2025-12-18
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Completed
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT03496805 2025-12-05
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Wake Forest University Health Sciences
Phase 2 Completed
NCT04019964 2025-10-23
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT06434909 2025-10-21
CYTALUXâ„¢for the Intraoperative Imaging of Prostate Cancer
Indiana University
Phase 2 Completed
NCT03939689 2025-10-14
ARROW
Progenics Pharmaceuticals, Inc.
Phase 2 Completed
NCT03716739 2025-09-23
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05081193 2025-09-22
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03458247 2025-09-05
OPTIMABI
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT05946603 2025-09-04
IS-002 Phase 2 Prostate Cancer Study
Intuitive Surgical
Phase 2 Completed
NCT03570827 2025-09-03
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT02874014 2025-08-22
Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT03606837 2025-07-22
PROSTATEP
University Hospital, Bordeaux
Phase 2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT02430480 2025-07-16
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06312670 2025-05-29
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04390880 2025-05-16
PROSPYL
VA Greater Los Angeles Healthcare System
Phase 2 Completed
NCT02788773 2025-05-15
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT04332744 2025-05-11
ZZ-First
MedSIR
Phase 2 Completed
NCT01162135 2025-05-04
Digoxin for Recurrent Prostate Cancer
Thomas Jefferson University
Phase 2 Completed
NCT02967458 2025-04-30
Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
Thomas Jefferson University
Phase 2 Completed
NCT04523207 2025-04-25
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
Phase 2 Completed
NCT04600336 2025-03-30
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03655886 2025-03-21
LoMP II
University Hospital, Ghent
Phase 2 Completed
NCT05137067 2025-03-21
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
Optimal Health Research
Phase 2 Completed
NCT04832958 2025-03-14
Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients
IRCCS San Raffaele
Phase 2 Completed
NCT01309672 2025-02-26
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed
NCT05653856 2025-01-24
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
Curium US LLC
Phase 2 Completed